CRISPR/Cas9 Patent Battle: What's Happened, What's Next?

With the gene editing pipeline at stake, academic research institutions are battling for ownership of the foundational patents in CRISPR/Cas9 technology. A new report from Datamonitor Healthcare spells out the IP challenges and provides a timeline of key patent decisions.

Patent Law Concept 3D Illustration

Gene editing currently occupies just a small corner of the regenerative medicine pipeline, but it represents a game-changing technology that could produce therapies to treat patients with genetically defined diseases who no longer have any other options. Given the high stakes and the high revenue potential, key academic and industry stakeholders are involved in an intense patent battle that is expected to play out for several years. The outcomes will significantly shape the gene editing market.

Gene editing involves adding, removing, or altering DNA using an engineering nuclease that performs a cut in the DNA, plus...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Market Intelligence

More from In Vivo